Genmab (GMAB) Financial Analysis & Valuation | Quarter Chart
Genmab (GMAB)
GMABPrice: $26.02
Fair Value: 🔒
🔒score
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a hum... more
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily i... more
Description
Shares
| Market Cap | $15.97B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Jan van de Winkel |
| IPO Date | 2009-06-01 | CAGR | — |
| Employees | 2,638 | Website | www.genmab.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 17.4% | Total Yield | 17.4% |
GMAB chart loading...
Fundamentals
Technicals
| Enterprise Value | $19.78B | P/E Ratio | 18.72 |
| Forward P/E | — | PEG Ratio | -0.27 |
| P/S Ratio | 1.07 | P/B Ratio | 2.72 |
| P/CF Ratio | 12.51 | P/FCF Ratio | 13.42 |
| EPS | $1.39 | EPS Growth 1Y | -59.7% |
| EPS Growth 3Y | -47.45% | EPS Growth 5Y | -50.48% |
| Revenue Growth 1Y | -34.41% | Gross Margin | 0.94% |
| Operating Margin | 0.4% | Profit Margin | 0.18% |
| ROE | 0.21% | ROA | 0.21% |
| ROCE | 0.51% | Current Ratio | 2.18 |
| Quick Ratio | 2.17 | Cash Ratio | 1.29 |
| Debt/Equity | 0.94 | Interest Coverage | 26.47 |
| Altman Z Score | 11.74 | Piotroski Score | 5 |